ESC 365 - DPP-4 inhibitors and SGLT2 inhibitors

ESC Premium Access

DPP-4 inhibitors and SGLT2 inhibitors - A mechanism for the future?

Session: Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease

Topic: Antiarrhythmic drugs

Speaker: Associate Professor D. Cherney (Toronto, CA)

About the speaker

Associate Professor David Cherney

Toronto (Canada)

2 presentations

0 follower

6 more presentations in this session

Opening remarks - Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease.

Speaker: Professor S. Del Prato (Pisa, IT)

Access

Why control glycemia?

Speaker: Professor L. Leiter (Toronto, CA)

Access

Clarifying the role for DPP-4 inhibitors in the treatment of patients with type 2 diabetes at risk of heart failure.

Speaker: Professor D. McGuire (Dallas, US)

Access

Q&A - Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease.

Speaker: Professor S. Del Prato (Pisa, IT)

Access

Clinical considerations - A perspective across specialties.

Speaker: Professor S. Del Prato (Pisa, IT) Professor D. McGuire (Dallas, US) Professor L. Leiter (Toronto, CA) Associate Professor D. Cherney (Toronto, CA)

Access

Access the full session

Considerations for cardiologists: further insights into treatment options for patients with type 2 diabetes and cardiovascular disease

Speakers: Associate Professor D. Cherney, Professor S. Del Prato, Professor L. Leiter, Professor D. McGuire, Professor S. Del Prato...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources